Generic Zelapar Availability
ZELAPAR (selegiline hydrochloride - tablet, orally disintegrating;oral)
Has a generic version of Zelapar been approved?
No. There is currently no therapeutically equivalent version of Zelapar available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zelapar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical and other dosage forms
Issued: July 15, 1997
Inventor(s): Gole; Dilip J. & Levinson; R. Saul & Wilkinson; Paul K. & Davies; J. Desmond
Assignee(s): Janssen Pharmaceutica Inc.
A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms is disclosed.Patent expiration dates:
- July 15, 2014✓
- July 15, 2014
Process for the preparation of a solid pharmaceutical dosage form
Issued: July 23, 2002
Inventor(s): Andrew William; Jordan & Joy Elaine; Saunders & Patrick; Kearney
Assignee(s): R. P. Scherer Corporation
A process for the preparation of a solid pharmaceutical dosage form comprising a carrier and, as active ingredient, a compound which exists, in solution, in an equilibrium between a free acid or free base form and a salt form, and for which there is a difference in volatility between the free acid or free base form and the salt form. The process includes the steps of solidifying a mixture of the compound and carrier in a solvent, and subsequently removing the solvent from the solidified mixture. A pH modifier is added to the mixture prior to solidification to shift the equilibrium to favor the less volatile form of the active ingredient.Patent expiration dates:
- March 1, 2016✓
- March 1, 2016
- Zelapar Consumer Information (Drugs.com)
- Zelapar orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Zelapar Consumer Information (Cerner Multum)
- Zelapar Advanced Consumer Information (Micromedex®)
- Zelapar Oral Advanced Consumer Information (Micromedex®)
- Selegiline Consumer Information (Wolters Kluwer)
- Selegiline orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Selegiline system Consumer Information (Wolters Kluwer)
- Selegiline Consumer Information (Cerner Multum)
- Selegiline transdermal Consumer Information (Cerner Multum)
- Selegiline Advanced Consumer Information (Micromedex®)
- Selegiline Oral Advanced Consumer Information (Micromedex®)
- Selegiline Transdermal Advanced Consumer Information (Micromedex®)
- Selegiline Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|